Modified GRF (1-29), Hexarelin Blend is a two-component peptide formulation supplied for controlled laboratory research involving growth hormone-axis receptor systems. Modified GRF (1-29) is a synthetic GHRH-related research peptide, while Hexarelin is a synthetic growth hormone secretagogue commonly evaluated in GHSR1a-associated models.
The formulation provides laboratories with a standardized sample for examining two receptor-associated signaling inputs within one defined experimental system. Studies may measure receptor activity, second-messenger responses, time-dependent molecular markers, or differences between blended and single-compound research conditions.
References to growth hormone release, pituitary responses, pulse patterns, or endocrine communication describe laboratory mechanisms only. They do not indicate that the blend changes hormone concentrations, metabolism, body composition, physical performance, recovery, or any other outcome in humans or animals.
Lot-specific analytical documentation is available through the Nordsci Certificate of Analysis Library.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
Modified GRF (1-29), Hexarelin Blend is a two-component peptide research formulation supplied for controlled laboratory analysis of GHRH receptor- and GHSR1a-associated signaling systems.
Laboratories may use the blend in receptor-binding assays, cell-based signaling models, comparative compound studies, and time-dependent molecular-response experiments. Because the formulation contains two peptides, appropriate controls are required before an observed result can be associated with a specific component or receptor pathway.
References to growth hormone release, pituitary activity, pulse timing, or endocrine signaling identify experimental mechanisms. They do not indicate that the blend changes growth hormone levels or produces physiological outcomes in humans or animals.
Modified GRF (1-29), Hexarelin Blend – Research Specifications:
| Product Format | Two-component peptide research blend |
| Contents | Modified GRF (1-29) and Hexarelin |
| Form | Lyophilized powder |
| Source | Chemical synthesis and compound-specific formulation |
| Purity / Identity | Refer to the lot-specific Certificate of Analysis |
| Analytical Documentation | Lot-specific documentation may report HPLC, mass spectrometry, or other applicable analytical results |
| Storage Conditions | Store sealed at −20°C or below and protect from light, heat, and moisture unless otherwise stated in the applicable documentation |
| Research Classification | Laboratory research and analytical use only |
| Restrictions | Not for human or animal consumption or in vivo, diagnostic, therapeutic, food, drug, cosmetic, or dietary-supplement use |
Modified GRF (1-29) is a synthetic GHRH-related research peptide commonly examined in models containing the growth hormone-releasing hormone receptor. Laboratory studies may measure receptor binding, receptor activation, cyclic adenosine monophosphate activity, or other predefined molecular endpoints.
Hexarelin is a synthetic growth hormone secretagogue research peptide commonly evaluated in GHSR1a-associated assay systems. Its inclusion provides a second receptor-associated input for controlled comparative studies.
Combining these compounds allows researchers to examine GHRH receptor- and GHSR1a-associated activity within one standardized formulation. The blend may be compared with individual CJC-1295 without DAC, commonly associated with Modified GRF (1-29) research, and Hexarelin research arms.
A blended formulation does not independently identify which component is associated with a measured response. Compound-specific controls, consistent assay conditions, and validated analytical procedures are required when pathway-level interpretation is needed.
Important Research Notice: Nordsci research materials are supplied with access to lot-specific analytical documentation. Researchers should consult the applicable Certificate of Analysis for reported identity and purity information.
THIS PRODUCT IS INTENDED EXCLUSIVELY FOR LABORATORY RESEARCH. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR IN VIVO, DIAGNOSTIC, THERAPEUTIC, FOOD, DRUG, COSMETIC, OR DIETARY-SUPPLEMENT USE.
The blend may be evaluated in controlled cellular systems designed to represent GHRH receptor- and GHSR1a-associated signaling. Applicable endpoints can include receptor activity, second-messenger measurements, and other assay-specific molecular markers.
Observed activity remains specific to the selected in vitro model. It should not be interpreted as evidence that the blend changes growth hormone concentrations in humans or animals.
Researchers may use the blend in pituitary-derived or other endocrine-associated cellular models. These experiments can characterize molecular responses under defined concentration ranges, exposure periods, sampling intervals, and environmental conditions.
The use of pituitary-derived cells identifies the experimental model. It does not indicate that the blend affects human or animal pituitary function or hormonal balance.
Controlled laboratory experiments may measure receptor-associated markers across predefined timepoints. This design can characterize assay timing and differences among blended, single-compound, vehicle, and untreated conditions.
Time-dependent molecular observations do not establish effects on hormone rhythms, sleep, metabolism, body composition, recovery, or other physiological outcomes.
Laboratories may compare the blended formulation with individual Modified GRF (1-29) or Hexarelin research arms. This structure can help distinguish blended observations from compound-specific assay responses.
Any difference between study arms should be interpreted only within the limitations of the selected model, controls, methods, concentration ranges, and analytical endpoints.
Modified GRF (1-29), Hexarelin Blend should be handled only by qualified laboratory personnel using established procedures for multi-component peptide research materials. Laboratories should document product receipt, lot identification, storage conditions, sample allocation, testing methods, and disposal.
No reconstitution volume, diluent selection, concentration, dosing, injection, administration, or in vivo application guidance is provided.
Protocol Design Considerations:
Note: This information is provided exclusively as a laboratory research reference. All work should be conducted by qualified personnel in appropriately equipped facilities and in accordance with applicable institutional requirements.
Lot-specific Certificates of Analysis provide analytical information associated with the applicable Modified GRF (1-29), Hexarelin Blend lot. Documentation may include identity, purity, testing methodology, and other reported analytical results.
Researchers should confirm that the lot number on the vial corresponds with the lot number shown on the applicable COA. Analytical findings apply only to the tested lot and should not be interpreted as evidence of clinical safety, effectiveness, or approval for human or veterinary use.
Nordsci Peptides supplies Modified GRF (1-29), Hexarelin Blend as a multi-component laboratory research material with access to lot-specific analytical documentation. Laboratories should evaluate formulation identity, reported analytical results, storage requirements, batch traceability, and institutional procurement standards before use.
IMPORTANT: This blend is sold exclusively for laboratory research and analytical use. It is not a drug, food, dietary supplement, cosmetic, or therapeutic product. It is not approved for human or veterinary use and must not be used for consumption, diagnosis, treatment, prevention, compounding, or any in vivo procedure.
